Current approach to treatments for prolactinomas

Area of Science:

• Endocrinology
• Oncology
• Neurosurgery

Background:

• Prolactinomas are the most common functional pituitary neoplasms, originating from lactotroph cells.
• Tumor effects stem from hyperprolactinemia or mass effect on surrounding structures.
• Management strategies differ for micro- and macroprolactinomas.

Purpose of the Study:

• To review the medical treatment of prolactinomas.
• To highlight differences in treating micro- versus macroprolactinomas.
• To discuss specialized management for pregnant patients and malignant prolactinomas.

Main Methods:

• Review of medical literature on prolactinoma treatment.
• Focus on dopamine agonist (DA) therapy.
• Comparison of DA efficacy for micro- and macroprolactinomas.

Main Results:

• Dopamine agonists (DA) are the first-line treatment for most prolactinomas.
• Cabergoline (CAB) achieves high rates of normoprolactinemia (80-100% for micro, 75-95% for macro).
• Surgery and radiation are second-line options for specific indications like DA intolerance or resistance.

Conclusions:

• Medical therapy with dopamine agonists is highly effective for prolactinomas.
• Cabergoline is the preferred agent due to its efficacy.
• Specialized approaches are necessary for pregnant patients and malignant prolactinomas.